PrEP Access and Coverage Act of 2026

Legislative bill overview

HR 7853 mandates insurance coverage for PrEP (pre-exposure prophylaxis) medications without cost-sharing, expands access through federal programs including Medicare/Medicaid and VA coverage, and requires equitable distribution across geographic regions and demographic groups. The bill addresses both insurance coverage barriers and supply chain gaps that currently limit access to HIV prevention medication.

Why is this important

PrEP is highly effective at preventing HIV infection but remains inaccessible to many people due to cost and insurance gaps, despite being FDA-approved since 2012. The bill could significantly reduce new HIV infections among high-risk populations while shifting some costs to federal and insurance systems rather than individuals.

Potential points of contention

• Cost implications: Expanded federal coverage and zero cost-sharing requirements will increase government and insurance spending; fiscal impact estimates needed
• Mandate scope: Requiring all insurance plans to cover PrEP without cost-sharing may face industry opposition and questions about proper insurance design
• Geographic equity requirements: Mandating equitable distribution across regions raises implementation questions about how to enforce and fund rural/underserved area access
• Definition of covered populations: Determining who qualifies for no-cost coverage involves clinical and equity decisions that could face disagreement